Arylpiperazines for management of benign prostatic hyperplasia: Design, synthesis, quantitative structure-activity relationships, and pharmacokinetic studies

Journal of Medicinal Chemistry

Volumn 54, Issue 1, 2011, Pages 302-311

  Sarswat, Amit ^a   Kumar, Rajeev ^a   Kumar, Lalit ^a   Lal, Nand ^a   Sharma, Smriti ^a   Prabhakar, Yenamandra S ^a   Pandey, Shailendra K ^a   Lal, Jawahar ^a   Verma, Vikas ^a   Jain, Ashish ^a   Maikhuri, Jagdamba P ^a   Dalela, Diwakar ^b   Kirti, ^b   Gupta, Gopal ^a   Sharma, Vishnu L ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; FLUTAMIDE; PIPERAZINE DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BLOOD BRAIN BARRIER; CANCER CELL; CELL STRAIN LNCAP; GENE EXPRESSION; HUMAN; IN VITRO STUDY; NONHUMAN; ORGAN WEIGHT; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT; TARGET ORGAN;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; EPITHELIAL CELLS; ESTROGEN RECEPTOR BETA; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PIPERAZINES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANDROGEN; TISSUE DISTRIBUTION;

EID: 78651062324     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101163m     Document Type: Article

References (42)

1. Prostate News (Nature Publishing Group). Prostate Cancer Prostatic Dis. 2009, 12, 211 - 214.
2. Liu, J.; Shimizu, K.; Konishi, F.; Kumamoto, S.; Kondo, R. The Anti-Androgen Effect of Ganoderol B Isolated from Ganoderma lucidum Bioorg. Med. Chem. 2007, 15, 4966
3. http://kidney.niddk.nih.gov/about/Research-Updates/UrologicDiseasesWin07/ 1.htm.
4. Kokontis, J. M.; Liao, S. Molecular Action of Androgen in the Normal and Neoplastic Prostate Vitam. Horm. 1999, 55, 219-307
5. Lepor, H.; Williford, W. O.; Barry, M. J.; Brawer, M. K.; Dixon, C. M.; Gormley, G.; Haakenson, C.; Machi, M.; Narayan, P.; Padley, R. J. The Efficacy of Terazosin, Finasteride, or both in Benign Prostatic Hyperplasia N. Engl. J. Med. 1996, 335, 533-539
6. Lepor, H. Landmark Studies Impacting the Medical Management of Benign Prostatic Hyperplasia Rev. Urol. 2003, 5 (Suppl. 5) S28-S35
7. Li, J.; Tripathi, R. C.; Tripathi, B. J. Drug-induced Ocular Disorders Drug Saf. 2008, 31, 127-141
8. Neumann, F. The Antiandrogen Cyproterone Acetate: Discovery, Chemistry, Basic Pharmacology, Clinical Use and Tool in Basic Research Exp. Clin. Endocrinol. 1994, 102, 1-32
9. Furr, B. J. A. The Development of Casodex (Bicalutamide): Preclinical Studies Eur. Urol. 1996, 29 (Suppl. 2) 83-95
10. Labrie, F. Mechanism of Action and Pure Antiandrogenic Properties of Flutamide Cancer 1993, 72, 3816-3827
11. Koch, H.; Flutamides, A. New Non-Steroidal Anti-Androgen Drugs Today 1984, 20, 561-574
12. Wysowski, D. K.; Freiman, J. P.; Tourtelot, J. B.; Horton, M. L. Fatal and Nonfatal Hepatotoxicity Associated with Flutamide Ann. Intern. Med. 1993, 118, 860-864
13. Kuhn, J. M.; Billebaud, T.; Navratil, H.; Moulonguet, A.; Friet, J.; Grise, P.; Louis, J. F.; Costa, P.; Husson, J. M.; Dahan, R.; Bertagna, C.; Edelstein, R. Prevention of the Transient Adverse Effects of a Gonadotropin Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Adiministration of an Antiandrogen (Nilutamide) N. Engl. J. Med. 1989, 321, 413-418
14. Furr, B. J. A. The Development of Casodex (Bicalutamide): Preclinical Studies Eur. Urol. 1996, 29 (Suppl. 2) 83-95
15. Kolvenbag, G. J. C. M.; Blackledge, G. R. P. Worldwide Activity and Safety of Bicalutamide: A Summary Review Urology 1996, 47 (Suppl. 1A) 70-79
16. Tucker, H.; Crook, J. W.; Chesterson, G. J. Nonsteroidal Antiandrogens. Synthesis and Structure-Activity Relationship of 3-Substituted Derivatives of 2-Hydroxypropionanilide J. Med. Chem. 1988, 31, 954-959
17. Verhelst, J.; Denis, L.; Van Vliet, P.; Van Poppel, H.; Braeckman, J.; Van Cangh, P.; Mattelaer, J.; DHulster, D.; Mahler, C. Endocrine Profiles during Administration of the New Non-steroidal Anti-androgen Casodex in Prostate Cancer Clin. Endocrinol. 1994, 41, 525-530
18. Dawson, L. A.; Chow, E.; Morton, G. Fulminant Hepatic Failure Associated with Bicalutamide Urology 1997, 49, 283-284
19. Ishioka, T.; Tanatani, A.; Nagasawa, K.; Hashimoto, Y. Anti-Androgens with Full Antagonistic Activity Toward Human Prostate Tumor LNCaP Cells with Mutated Androgen Receptor Bioorg. Med. Chem. Lett. 2003, 13, 2655-2658
20. Hashimoto, Y. Structural Development of Biological Response Modifiers Based on Thalidomide Bioorg. Med. Chem. 2002, 10, 461-479
21. Ishioka, T.; Kubo, A.; Koiso, Y.; Nagasawa, K.; Itai, A.; Hashimoto, Y. Novel Non-steroidal/Non-anilide Type Androgen Antagonists with an Isoxazolone Moiety Bioorg. Med. Chem. 2002, 10, 1555-1566
22. Takahashi, H.; Ishioka, T.; Koiso, Y.; Sodeoka, M.; Hashimoto, Y. Anti-Androgenic Activity of Substituted Azo- and Azoxy-Benzene Derivatives Biol. Pharm. Bull. 2000, 23, 1387-1390
23. Schlienger, N.; Lund, B. W.; Pawlas, J.; Badaloss, F.; Bertozzi, F.; Lewinsky, R.; Fejzic, A.; Thygesen, M. B.; Tabatabaei, A.; Bradley, S. R.; Gardell, L. R.; Piu, F.; Olsson, R. Synthesis, Structure Activity Relationships and Characterization of Novel Non-steroidal and Selective Androgen Receptor modulators J. Med. Chem. 2009, 52, 7186-7191
24. Hamann, L. G.; Higuchi, R. I.; Zhi, L.; Edwards, J. P.; Wang, X.- N.; Marschke, K. B.; Kong, J. W.; Farmer, L. J.; Jones, T. K. Synthesis and Biological Activity of a Novel Series of Nonsteroidal, Peripherally Selective Androgen Receptor Antagonists Derived from 1,2-Dihydropyridono[5,6- g ]quinolines J. Med. Chem. 1998, 41, 623-639
25. Kong, J. W.; Hamann, L. G.; Ruppar, D. A.; Edwards, J. P.; Marschke, K. B.; Jones, T. K. Effects of Isosteric Pyridone Replacements in Androgen Receptor Antagonists Based on 1,2-Dihydro- and 1,2,3,4-Tetrahydro-2,2-dimethyl-6- trifluoromethyl-8-pyridono[5,6- g ]-quinolines Bioorg. Med. Chem. Lett. 2000, 10, 411-414
26. Ohtsu, H.; Xiao, Z.; Ishida, J.; Nagai, M.; Wang, H.-K.; Itokawa, H.; Su, C.-Y.; Shih, C.; Chiang, T.; Chang, E.; Lee, Y.; Tsai, M.-Y.; Chang, C.; Lee, K.-H. Antitumor Agents 217. Curcumin Analogues as Novel Androgen Receptor Antagonists with Potential as Anti-Prostate Cancer Agents J. Med. Chem. 2002, 45, 5037-5042
27. Ohtsu, H.; Itokawa, H.; Xiao, Z.; Su, C.-Y.; Shih, C. C.-Y.; Chiang, T.; Chang, E.; Lee, Y.; Chiu, S.-Y.; Chang, C.; Lee, K.-H. Antitumor Agents 222. Synthesis and Anti-Androgen Activity of New Diarylheptanoids Bioorg. Med. Chem. 2003, 11, 5083-5090
28. Mohler, M. L.; Bohl, C. E.; Jones, A.; Coss, C. C.; Naraynan, R.; He, Y.; Hwang, D. J.; Dalton, J. T.; Miller, D. D. Non-steroidal Selective Androgen Receptor Modulators (SARMs) Dissociating the Anabolic and Androgenic Activities of the Androgenic Receptor for Therapeutic Benefit J. Med. Chem. 2009, 52, 3597-3617
29. Salvati, M. E.; Balog, A.; Wei, D. D.; Pickering, D.; Attar, R. M.; Geng, J.; Rizzo, C. A.; Hunt, J. T.; Gottardis, M. M.; Weinmann, R.; Martinez, R. Identification of a Novel Class of Androgen Receptor Antagonists Based on the Bicyclic-1H-isoindole-1,3(2H)-dione Nucleus Bioorg. Med. Chem. Lett. 2005, 15, 389-393
30. Reid, P.; Kantoff, P.; Oh, W. Antiandrogens in Prostate Cancer Invest. New Drugs 1999, 17, 271-284
31. Kinoyama, I.; Taniguchi, N.; Yoden, T.; Koutoku, H.; Furutani, T.; Kudoh, M.; Okada, M. Synthesis and Pharmacological Evaluation of Novel Arypiperazine Derivatives as Nonsteroidal Androgen Receptor Antagonists Chem. Pharm. Bull. 2004, 52, 1330-1333
32. Kinoyama, I.; Taniguchi, N.; Kawaminami, E.; Nozawa, E.; Koutoku, H.; Furutani, T.; Kudoh, M.; Okada, M. N -Arylpiperazine-1-carboxamide Derivatives: A Novel Series of Orally Active Nonsteroidal Androgen Receptor Antagonists Chem. Pharm. Bull. 2005, 53, 402-409
33. Kinoyama, I.; Taniguchi, N.; Toyoshima, A.; Nozawa, E.; Kamikubo, T.; Imamura, M.; Matsuhisa, A.; Samizu, K.; Kawanimani, E.; Niimi, T.; Hamada, N.; Koutoku, H.; Furutani, T.; Kudoh, M.; Okada, M.; Ohta, M.; Tsukamoto, S. (+)-(2R,5S)-4-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6- (trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (YM580) as an Orally Potent and Peripherally Selective Nonsteroidal Androgen Receptor Antagonist J. Med. Chem. 2006, 49, 716-726
34. Kim, J.; Coetzee, G. A. Prostate Specific Antigen Gene Regulation by Androgen Receptor J. Cell Biochem. 2004, 93 (2) 233-241
35. Kizu, R.; Okamura, K.; Toriba, A.; Kakishima, H.; Mizokami, A.; Burnstein, K. L.; Hayakawa, K. A Role of Aryl Hydrocarbon Receptor in the Antiandrogenic Effects of Polycyclic Aromatic Hydrocarbons in LNCaP Human Prostate Carcinoma Cells Arch. Toxicol. 2003, 77, 335-343
36. Bauman, D. R.; Steckelbroeck, S.; Peehl, D. M.; Penning, T. M. Transcript Profiling of the Androgen Signal in Normal Prostate, Benign Prostatic Hyperplasia, and Prostate Cancer Endocrinology 2006, 147, 5806-5816
37. Davies., B.; Morris, T. Physiological Parameters in Laboratory Animals and Humans Pharm. Res. 1993, 10, 1093-1095
38. ChemDraw Ultra 6.0 and Chem 3D Ultra. Cambridge Soft Corp., Cambridge, MA.
39. Todeschini, R.; Consonni, V.; Mauri, A.; Pavan, M. DRAGON software version 5.0, 2005; http://disat.unimib.it/chm/Dragon.htm.
40. Prabhakar, Y. S. A Combinatorial Approach to the Variable Selection in Multiple Linear Regression: Analysis of Selwood et al. Data Set-A Case Study QSAR Comb. Sci. 2003, 22, 583-595
41. Ellem, S. J.; Risbridger, G. P. Treating Prostate Cancer: A Rationale for Targeting Local Oestrogens Nat. Rev. Cancer 2007, 7, 621-627
42. Padayatty, S. J.; Marcelli, M.; Shao., T. C. Lovastatin-Induced Apoptosis in Prostate Stromal Cells J. Clin. Endocrinol. Metab. 1997, 82, 1434-1439